Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Contributed by: GlobeNewswire

Tags

EAN congress

More Like This

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

PR Newswire associated0

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines